Evommune, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
EVMN$7.84+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)
| Three Months Ended | ||||
|---|---|---|---|---|
| March 31, | ||||
| 2026 · 2025 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $ | (21,674) | $ | (14,557) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation expense | 3,454 | 544 | ||
| Net amortization of premiums and accretion of discounts on investments | (792) | (425) | ||
| Depreciation and amortization | 349 | 377 | ||
| Change in fair value of convertible preferred stock forward | — | 125 | ||
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other assets | (85) | (3,964) | ||
| Accounts payable | (3,749) | (691) | ||
| Accrued liabilities | (4,813) | (2,102) | ||
| Operating lease liabilities | (193) | (206) | ||
| Deferred revenue | — | (3,000) | ||
| Net cash used in operating activities | (27,503) | (23,899) | ||
| Cash flows from investing activities: | ||||
| Purchases of investments | (108,776) | — | ||
| Maturities of investments | 23,500 | 13,500 | ||
| Purchase of property and equipment | (83) | — | ||
| Net cash (used in) provided by investing activities | (85,359) | 13,500 | ||
| Cash flows from financing activities: | ||||
| Proceeds from private placement financing, net of transaction costs | 117,198 | — | ||
| Proceeds from exercise of stock options | — | 2 | ||
| Principal payments of finance lease liability | (87) | (96) | ||
| Principal payments of financing obligation | — | (58) | ||
| Net cash provided by (used in) financing activities | 117,111 | (152) | ||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 4,249 | (10,551) | ||
| Cash, cash equivalents and restricted cash, beginning of year | 45,478 | 16,463 | ||
| Cash, cash equivalents and restricted cash, end of year | $ | 49,727 | $ | 5,912 |
| Components of cash, cash equivalents, and restricted cash | ||||
| Cash and cash equivalents | 48,318 | 5,704 | ||
| Restricted cash | 1,409 | 208 | ||
| Total cash, cash equivalents, and restricted cash | 49,727 | 5,912 | ||
| Supplemental cash flow disclosures: | ||||
| Cash paid for interest | $ | 4 | $ | 4 |
| Non-cash investing and financing activities: | ||||
| Unpaid fixed asset purchases | 38 | — | ||
| Vesting of early exercised stock options | 10 | 10 | ||
| Operating lease liabilities arising from obtaining right-of-use assets | 6,682 | — | ||
| Assets acquired under finance leases | 652 | — | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.